ACOR - Acorda shares surge 27% on INBRIJA distribution and supply deal

Acorda Therapeutics (ACOR) shares surge more than 27% post market after inking distribution and supply agreements with Esteve Pharmaceuticals to commercialize INBRIJA 33 mg (levodopa inhalation powder, hard capsules) in Spain.INBRIJA is indicated in the EU for the intermittent treatment of episodic motor fluctuations in adult patients with Parkinson’s disease treated with a levodopa/dopa-decarboxylase inhibitor. Under the terms of the supply agreement, Acorda will receive a significant double-digit percent of the selling price of INBRIJA in Spain in exchange for supply of the product. Esteve expects to launch the drug in Spain in the fourth quarter of 2022.

For further details see:

Acorda shares surge 27% on INBRIJA distribution and supply deal